•
Mar 31, 2021

Akoya Q1 2021 Earnings Report

Akoya's first quarter performance demonstrated continued adoption of Codex and Phenoptics solutions, with strong financial results and progress across metrics.

Key Takeaways

Akoya Biosciences reported total revenue of $12.2 million for the first quarter of 2021, compared to $11.0 million in the first quarter of 2020. Product revenue was $10.0 million, with instrument revenue at $6.8 million and reagent revenue at $2.5 million.

Total revenue for the first quarter of 2021 was $12.2 million, compared to $11.0 million in the first quarter of 2020.

Product revenue was $10.0 million in the first quarter of 2021, compared to $8.9 million in the prior year period.

Instrument revenue was $6.8 million in the first quarter 2021, compared to $6.7 million in the first quarter 2020.

Reagent revenue was $2.5 million in the first quarter 2021, compared to $2.1 million in the first quarter 2020.

Total Revenue
$12.2M
Previous year: $11M
+10.8%
EPS
-$3.54
Previous year: -$0.0741
+4676.7%
Gross Profit
$7.41M
Previous year: $6.7M
+10.6%
Cash and Equivalents
$11.7M
Free Cash Flow
-$5.31M
Total Assets
$74.5M

Akoya

Akoya

Akoya Revenue by Segment

Forward Guidance

Akoya expects full year 2021 revenue to be at least $52.0 million. The second quarter of 2021 is expected to have revenue growth of approximately 45% over the prior year quarter.

Revenue & Expenses

Visualization of income flow from segment revenue to net income